Literature DB >> 22341446

Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Baochun Zhang1, Sven Kracker, Tomoharu Yasuda, Stefano Casola, Matthew Vanneman, Cornelia Hömig-Hölzel, Zhe Wang, Emmanuel Derudder, Shuang Li, Tirtha Chakraborty, Shane E Cotter, Shohei Koyama, Treeve Currie, Gordon J Freeman, Jeffery L Kutok, Scott J Rodig, Glenn Dranoff, Klaus Rajewsky.   

Abstract

B cells infected by Epstein-Barr virus (EBV), a transforming virus endemic in humans, are rapidly cleared by the immune system, but some cells harboring the virus persist for life. Under conditions of immunosuppression, EBV can spread from these cells and cause life-threatening pathologies. We have generated mice expressing the transforming EBV latent membrane protein 1 (LMP1), mimicking a constitutively active CD40 coreceptor, specifically in B cells. Like human EBV-infected cells, LMP1+ B cells were efficiently eliminated by T cells, and breaking immune surveillance resulted in rapid, fatal lymphoproliferation and lymphomagenesis. The lymphoma cells expressed ligands for a natural killer (NK) cell receptor, NKG2D, and could be targeted by an NKG2D-Fc fusion protein. These experiments indicate a central role for LMP1 in the surveillance and transformation of EBV-infected B cells in vivo, establish a preclinical model for B cell lymphomagenesis in immunosuppressed patients, and validate a new therapeutic approach. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22341446      PMCID: PMC3313622          DOI: 10.1016/j.cell.2011.12.031

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  49 in total

Review 1.  Epstein-Barr virus: exploiting the immune system.

Authors:  D A Thorley-Lawson
Journal:  Nat Rev Immunol       Date:  2001-10       Impact factor: 53.106

2.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

3.  Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes.

Authors:  Michael Peitz; Kurt Pfannkuche; Klaus Rajewsky; Frank Edenhofer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 4.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas.

Authors:  L Pasqualucci; P Neumeister; T Goossens; G Nanjangud; R S Chaganti; R Küppers; R Dalla-Favera
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

6.  Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.

Authors:  A Diefenbach; E R Jensen; A M Jamieson; D H Raulet
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

Review 7.  Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.

Authors:  R Khanna; S R Burrows
Journal:  Annu Rev Microbiol       Date:  2000       Impact factor: 15.500

8.  Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology.

Authors:  Efsevia Vakiani; Katia Basso; Ulf Klein; Mahesh M Mansukhani; Gopeshwar Narayan; Paula M Smith; Vundavalli V Murty; Riccardo Dalla-Favera; Laura Pasqualucci; Govind Bhagat
Journal:  Hematol Oncol       Date:  2008-12       Impact factor: 5.271

Review 9.  Tumour necrosis factor and cancer.

Authors:  Frances Balkwill
Journal:  Nat Rev Cancer       Date:  2009-04-03       Impact factor: 60.716

Review 10.  The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis.

Authors:  Thomas Blankenstein; Zhihai Qin
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

View more
  75 in total

Review 1.  Animal models of tumorigenic herpesviruses--an update.

Authors:  Dirk P Dittmer; Blossom Damania; Sang-Hoon Sin
Journal:  Curr Opin Virol       Date:  2015-10       Impact factor: 7.090

Review 2.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

3.  Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis.

Authors:  Thomas Sommermann; Tomoharu Yasuda; Jonathan Ronen; Tristan Wirtz; Timm Weber; Ulrike Sack; Rebecca Caeser; Jingwei Zhang; Xun Li; Van Trung Chu; Anna Jauch; Kristian Unger; Daniel J Hodson; Altuna Akalin; Klaus Rajewsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-10       Impact factor: 11.205

4.  Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.

Authors:  Il-Kyu Choi; Zhe Wang; Qiang Ke; Min Hong; Yu Qian; Xiujuan Zhao; Yuting Liu; Hye-Jung Kim; Jerome Ritz; Harvey Cantor; Klaus Rajewsky; Kai W Wucherpfennig; Baochun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

5.  Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.

Authors:  Shu-Chun Tsai; Sue-Jane Lin; Cheau-Jye Lin; Ya-Ching Chou; Jiun-Han Lin; Te-Huei Yeh; Mei-Ru Chen; Li-Min Huang; Meng-You Lu; Ya-Chi Huang; Huan-Yun Chen; Ching-Hwa Tsai
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

6.  Oncogenic herpesviruses sending mixed signals.

Authors:  D Michiel Pegtel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-19       Impact factor: 11.205

7.  RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.

Authors:  A Chanut; F Duguet; A Marfak; A David; B Petit; M Parrens; S Durand-Panteix; M Boulin-Deveza; N Gachard; I Youlyouz-Marfak; D Bordessoule; J Feuillard; N Faumont
Journal:  Leukemia       Date:  2013-09-23       Impact factor: 11.528

8.  The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies.

Authors:  Konstantinos Liapis; Andrew Clear; Andrew Owen; Rita Coutinho; Paul Greaves; Abigail M Lee; Silvia Montoto; Maria Calaminici; John G Gribben
Journal:  Blood       Date:  2013-05-07       Impact factor: 22.113

9.  LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.

Authors:  Shi-Dong Ma; Xuequn Xu; Julie Plowshay; Erik A Ranheim; William J Burlingham; Jeffrey L Jensen; Fotis Asimakopoulos; Weihua Tang; Margaret L Gulley; Ethel Cesarman; Jenny E Gumperz; Shannon C Kenney
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

Review 10.  Inflammatory networks and immune surveillance of pancreatic carcinoma.

Authors:  Robert H Vonderheide; Lauren J Bayne
Journal:  Curr Opin Immunol       Date:  2013-02-17       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.